Cogent Biosciences, Inc.
COGT
Rang in Aktien
#3239
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aktienkurs
$31.49
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$5.46B
Veränderung (1 Tag)
0.81%
Veränderung (1 Jahr)
112.08%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Kategorie
Healthcare
Kursverlauf für Cogent Biosciences, Inc. (COGT)
Höchster Schlusskurs: $30.19 am 2026-10-01
Niedrigster Schlusskurs: $44.44 am 2018-03-01
Niedrigster Schlusskurs: $44.44 am 2018-03-01
Kursverlauf der Aktie von Cogent Biosciences, Inc. von 2018 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.50 | -4.01% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
